Skip to main content
. Author manuscript; available in PMC: 2009 Jul 30.
Published in final edited form as: Alzheimer Dis Assoc Disord. 2008;22(3):209–221. doi: 10.1097/WAD.0b013e31816653bc

Fig 2.

Fig 2

Raw data for ADL versus Duration of Illness (symptoms) for A) NO-RX group (no medications), B) CI group, and C) COMBO group of subjects. Thin lines connect data for an individual (subject), while the thick line is the best fitting OLS regression line for the data. There is shallowing of the slope for the OLS regression lines going from NO-RX and CI to COMBO that is consistent with a slower rate of functional decline in the COMBO group.